BioNTech
NEWS
New mutations of the SARS-CoV-2 virus are continuing to be discovered. As we’ve seen from the most common variants of the virus, infectiousness appears to be the trait most familiar to all of them.
The U.S. FDA expanded the Emergency Use Authorization for the Pfizer and BioNTech vaccine to include adolescents ages 12 to 15 after clinical data showed 100% efficacy response.
Please check out the biopharma industry’s COVID-19 stories that are trending for May 11, 2021.
BioNTech will open a state-of-the-art manufacturing facility in Singapore to support a global supply of mRNA-based vaccines and therapeutics.
On Thursday, Pfizer Chief Executive Officer Albert Bourla who is “not at all” in favor of the U.S. position, stated that the real challenge is manufacturing capacity.
With 2020 holding a record number of biotech IPOs, this year is lining up to come close. Three more Bay Area life science companies are just about ready to hit the Nasdaq, adding to the growing list for 2021.
Six months after receiving Emergency Use Authorization from the U.S. FDA for COVID-19 vaccines, Pfizer/BioNTech and Moderna are planning to seek full approval for the preventative medications.
There’s a fair amount of new information coming out about COVID-19 and vaccines. Here’s a roundup of some of the top stories.
While the U.S. had been one of a few rich nations holding out – along with Canada, the European Union and Britain – on some level, Wednesday’s announcement of support for the proposal is not unexpected.
JOBS
IN THE PRESS